EMA Refused: Adlumiz (anamorelin hydrochloride) — Helsinn Birex Pharmaceuticals Ltd.

View source ↗

Summary

EMA refused Adlumiz (anamorelin hydrochloride) from Helsinn Birex Pharmaceuticals Ltd., a decision affecting its use for cachexia/anorexia in non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anorexia
• Cachexia
• Carcinoma Non-small-cell Lung

Drugs mentioned

• Adlumiz (anamorelin hydrochloride)

Snippet

Status: Refused. Therapeutic area: Cachexia;Anorexia;Carcinoma, Non-Small-Cell Lung. MAH: Helsinn Birex Pharmaceuticals Ltd.. Decision date: 16/11/2017